As of 11:01 on April 7, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) fell by 14.02%. In terms of constituent stocks, WuXi XDC (02268) led the decline by 22.24%, WuXi Biologics (02269) fell by 22.09%, BeiGene (06160) fell by 18.23%, Ascentage Pharma-B (06855) fell by 17.95%, and Akeso Biologics (09926) fell by 17.87%. Hong Kong Pharmaceutical ETF (159718) fell 10.00%, the latest price was 0.66 yuan, and the intraday turnover has reached 17.4536 million yuan, with a turnover rate of 9.76%.

As of 11:00 on April 7, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) fell by 4.57%. In terms of constituent stocks, Yirui Technology (688301) led by 11.37%, United Imaging Medical (688271) rose 4.18%, and Huitai Medical (688617) rose 1.06%; Pharmaron (300759) led the decline by 13.12%, WuXi AppTec (603259) fell by 10.00%, and Zhifei Biologics (300122) fell by 8.92%. Medical Innovation ETF (516820) fell 4.27%, the latest price was 0.34 yuan, and the intraday turnover has reached 83.7087 million yuan, with a turnover rate of 5.13%.

In the long run, as of April 3, 2025, Hong Kong stock pharmaceutical ETFs have risen by 2.10% in the past 1 week, ranking 1/4 of comparable funds. Healthcare Innovation ETF has risen 0.86% over the last 1 week.

In terms of scale, the latest scale of the medical innovation ETF reached 1.711 billion yuan. The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 5.5804 million yuan, and the latest financing balance reached 76.4197 million yuan.

On the news side, a few days ago, the State Food and Drug Administration issued the "Measures on Optimizing the Whole Life Cycle Supervision to Support the Innovation and Development of High-end Medical Devices (Draft for Comments)", launching a series of innovation support policies for cutting-edge fields such as medical robots and artificial intelligence medical devices, including the implementation of the "innovation special review" procedure for domestic and international leading high-end medical devices, and clarifying the registration guidance policies for cutting-edge technologies such as artificial intelligence and brain-computer interface.

Guojin Securities believes that in terms of overall pharmaceutical allocation, innovative drugs and some generic drugs continue to be the top priority of the layout, and the policy changes of the commercial insurance catalog, the expected landing of centralized procurement/national talks, and the release of data from the American Oncology Conference (AACR and ASCO) will continue to bring follow-up stock price catalytic opportunities, and the key is to find the expected difference in individual stocks. The reversal of prosperity and the improvement of performance after the first quarter report will also bring individual stock investment opportunities in the left sectors such as chain pharmacies, equipment, CXO, generic drugs, traditional Chinese medicine, and medical services, which are recommended to be actively grasped.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of March 31, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are WuXi Biologics (02269), BeiGene (06160), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), Sino Biopharma (01177), CSPC Pharmaceutical Group (01093), Zai Lab (09688), Ali Health (00241), and Hansoh Pharma ( 03692), the top 10 weighted stocks accounted for 59.76% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of March 31, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Mindray Medical (300760), Aier Ophthalmology (300015), United Imaging Medical (688271), Kelun Pharmaceutical (002422), Huadong Medicine (000963), Changchun High-tech (000661), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.49%.